New Drug Approvals

Home » COMPANIES » Boehringer-Ingelheim …A Well-Balanced Pipeline

Boehringer-Ingelheim …A Well-Balanced Pipeline

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Archives

Categories

Recent Posts

Blog Stats

  • 4,482,327 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,841 other subscribers

add to any

Share

Promising Drugs in Boehringer-Ingelheim Pipeline

A Well-Balanced Pipeline
Boehringer Ingelheim has a rich pipeline showing a number of new molecular entities and a high share of products in late phase development. The company has brought a range of products from its own research & development to market. A number of these drugs have either achieved blockbuster status with annual sales exceeding one billion US dollars or have blockbuster potential.
Compound* Clinical phase Indication Therapeutic principle Mode of action
Olodaterol Submitted Chronic obstructive pulmonary Disease (COPD) Long-acting beta-agonist Bronchodilation
Tiotropium Submitted Cystic fibrosis (CF) Bronchodilatator Long Acting Muscarinic Antagonist
Afatinib Phase III Breast cancer Signal transduction inhibition Novel irreversible ErbB Family blocker
Afatinib Phase III Head and neck cancer Signal transduction inhibition Novel irreversible ErbB Family blocker
Deleobuvir
(BI 207127)
Phase III Hepatitis C Direct acting antiviral small molecule Oral NS5B RNA-dependent polymerase inhibitor
Empagliflozin Phase III Diabetes mellitus
type II
SGLT-2-inhibitor Inhibition of glucose transporter-2
Faldaprevir
(BI 201335)
Phase III Hepatitis C Direct acting antiviral small molecule Oral HCV NS3/4A protease inhibitor
Nintedanib Phase III Non-small cell lung cancer (NSCLC) Angiogenesis inhibition Triple angiokinase inhibitor, simultaneously blocks VEGFR, FGFR, PDGFR
Nintedanib Phase III Ovarian cancer Angiogenesis inhibition Triple angiokinase inhibitor, simultaneously blocks VEGFR, FGFR, PDGFR
Nintedanib Phase III Idiopathic pulmonary fibrosis (IPF) Anti-fibrotic kinase inhibition Anti-fibrotic kinase inhibitor
Tiotropium Phase III Asthma Bronchodilatator Long Acting Muscarinic Antagonist
Volasertib Phase III Various cancer types Cell-cycle kinase inhibition PLK-1 antagonist

* These are investigational agents; their safety and efficacy have not yet been established.

Status: April 2013

Successful Products from our Boehringer-Ingelheim Research & Development

Product name First launch Active ingredient Indication
Gilotrif™ 2013 Afatinib Non-small cell lung cancer (NSCLC)
Trajenta® 2011 Linagliptin Diabetes mellitus type II
Pradaxa® 2010
2008
Dabigatran etexilate Stroke prevention in atrial fibrillationPrevention of venous thromboembolic events (VTE) in adults
Spiriva®
Respimat Soft Mist™ InhalerSpiriva®
2007
2002
Tiotropium COPD
Micardis® 1998 Telmisartan Essential hypertension
Sifrol® / Mirapex® /Mirapexin® 20061997 Pramipexole Restless legs syndrome (RLS)
Parkinson’s disease (PD)
Viramune® 1996 Nevirapine HIV/AIDS

Partnering with Boehringer-Ingelheim

Partnering with us

Research & Development

Research & Development

Oncology Websites

No flash player detected. For optimized usage of this website your browser should support shockwave flash. For downloading see Macromedia Flash Player


Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

DR ANTHONY CRASTO

Follow New Drug Approvals on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,841 other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Personal Links

View Full Profile →

bloglovin

Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.